Michael Gaito

Mr. Gaito is a Managing Director in J.P. Morgan’s Healthcare Investment Banking group responsible for the firm’s West Coast Life Sciences practice. He has been with J.P. Morgan and its predecessor firms for more than 18 years, beginning with Hambrecht & Quist’s Investment Banking group, focusing on the pharmaceutical industry. During this time, Mr. Gaito has advised clients on transactions representing more than $21 billion, with a focus on strategic advisory and financing assignments for biotechnology and pharmaceutical companies worldwide. His recent transactions include senior lead left bookrunner and stabilization agent on Clovis Pharmaceuticals $288mm convertible bond offering, senior lead left bookrunner and stabilization agent on Jazz Pharmaceuticals’ $575mm convertible bond offering, senior lead left bookrunner and stabilization agent ZS on Pharma’s $123mm IPO, sole bookrunner on Sangamo BioSciences’ $100mm follow-on offering, lead strategic advisor on Edison Pharmaceuticals’ $4.3bn strategic collaboration with Dainippon Sumitomo, senior lead left bookrunner and stabilization agent on Ultragenyx Pharmaceutical’s IPO and first follow-on offering, senior lead left bookrunner and stabilization agent on PTC Therapeutics IPO and follow-on offering, bookrunner and stabilization agent on Ophthotech’s IPO and follow-on offering, sole bookrunner on Pharmacyclics’ $207mm follow-on offering, sole strategic advisor on Kai Pharmaceuticals’ $315mm sale to Amgen, sole strategic advisor on Jazz Pharmaceuticals’ all-stock merger with Azur Pharmaceuticals creating Jazz Pharmaceuticals PLC, sole strategic advisor on Amira Pharmaceuticals’ $475mm sale to Bristol-Myers Squibb, and sole strategic advisor on Calistoga Pharmaceuticals’ $600mm sale to Gilead. Mr. Gaito received his AB degree from Princeton University and his MBA from Columbia University, and lives with his wife and two daughters in San Francisco.